Johnetta Blakely

440 total citations
7 papers, 218 citations indexed

About

Johnetta Blakely is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Johnetta Blakely has authored 7 papers receiving a total of 218 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Johnetta Blakely's work include Lung Cancer Research Studies (5 papers), Cancer therapeutics and mechanisms (3 papers) and Neuroendocrine Tumor Research Advances (2 papers). Johnetta Blakely is often cited by papers focused on Lung Cancer Research Studies (5 papers), Cancer therapeutics and mechanisms (3 papers) and Neuroendocrine Tumor Research Advances (2 papers). Johnetta Blakely collaborates with scholars based in United States, Germany and France. Johnetta Blakely's co-authors include Egbert F. Smit, Piotr Serwatowski, Martin Reck, Mark A. Socinski, Aleksandra Szczęsna, Jacek Jassem, Nick Thatcher, Coleman K. Obasaju, Paul Lorigan and Nina Karaseva and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Johnetta Blakely

7 papers receiving 212 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Johnetta Blakely United States 5 174 112 79 71 10 7 218
V. Westeel France 8 262 1.5× 114 1.0× 85 1.1× 205 2.9× 15 1.5× 20 334
Galina Statsenko Russia 9 200 1.1× 149 1.3× 75 0.9× 85 1.2× 9 0.9× 25 238
Kim Norris United States 3 219 1.3× 182 1.6× 55 0.7× 100 1.4× 6 0.6× 8 249
J.R. Fischer Germany 9 247 1.4× 75 0.7× 78 1.0× 191 2.7× 19 1.9× 20 300
S. Morris Switzerland 7 243 1.4× 93 0.8× 53 0.7× 123 1.7× 19 1.9× 13 267
Gloria Borra Italy 6 132 0.8× 18 0.2× 58 0.7× 130 1.8× 34 3.4× 14 213
Chandrikha Chandrasekharan United States 10 172 1.0× 137 1.2× 41 0.5× 33 0.5× 19 1.9× 35 247
H Ikegami Japan 5 359 2.1× 269 2.4× 194 2.5× 91 1.3× 7 0.7× 8 411
Jane Hurwitz United Kingdom 3 101 0.6× 100 0.9× 117 1.5× 31 0.4× 11 1.1× 3 188
José Antonio López-Vilariño Spain 7 133 0.8× 83 0.7× 83 1.1× 44 0.6× 14 1.4× 21 184

Countries citing papers authored by Johnetta Blakely

Since Specialization
Citations

This map shows the geographic impact of Johnetta Blakely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johnetta Blakely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johnetta Blakely more than expected).

Fields of papers citing papers by Johnetta Blakely

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johnetta Blakely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johnetta Blakely. The network helps show where Johnetta Blakely may publish in the future.

Co-authorship network of co-authors of Johnetta Blakely

This figure shows the co-authorship network connecting the top 25 collaborators of Johnetta Blakely. A scholar is included among the top collaborators of Johnetta Blakely based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johnetta Blakely. Johnetta Blakely is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
2.
Chiappori, Alberto, Marshall T. Schreeder, Joe Stephenson, et al.. (2012). A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. British Journal of Cancer. 106(5). 839–845. 37 indexed citations
4.
Stepanski, Edward, Arthur C. Houts, Lee S. Schwartzberg, et al.. (2009). Second- and Third-line Treatment of Patients With Non–Small-Cell Lung Cancer With Erlotinib in the Community Setting: Retrospective Study of Patient Healthcare Utilization and Symptom Burden. Clinical Lung Cancer. 10(6). 426–432. 6 indexed citations
5.
Chiappori, Alberto, Marshall T. Schreeder, Johnetta Blakely, et al.. (2009). A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC). Journal of Clinical Oncology. 27(15_suppl). 3576–3576. 9 indexed citations
6.
Socinski, Mark A., Egbert F. Smit, Paul Lorigan, et al.. (2009). Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(28). 4787–4792. 159 indexed citations
7.
Blakely, Johnetta, Frederick M. Schnell, Paul Kaywin, et al.. (2006). Phase II trial of pemetrexed (P) and gemcitabine (G) as first-line chemotherapy for elderly and/or poor performance status patients with stage IIIB/IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 24(18_suppl). 17031–17031. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026